PharMerica Corporation (PMC) - NYSE
  • Fri, Feb. 26, 12:45 PM
    | Fri, Feb. 26, 12:45 PM | 4 Comments
  • Jan. 10, 2014, 12:47 PM
    | Jan. 10, 2014, 12:47 PM | 2 Comments
  • Dec. 4, 2013, 5:37 PM
    • Top Gainers, as of 5:15 p.m.: PBYI +10.4%. KFY +4.4%. ZLC +3.9%. PMC +3.3%. CPT +2.9%.
    • Top Losers, as of 5:15 p.m.: WTSL -15.7%. SNPS -4.4%. BRE -3.9%. ARO -3.8%. ASGN -3.5%.
    | Dec. 4, 2013, 5:37 PM
  • Nov. 5, 2013, 12:49 PM
    • PharMerica (PMC +25.7%) soars after smashing the estimate of analysts with its Q3 report.
    • Results were boosted by cost-containment measures and an industry-leading generic dispensing rate of 83.3%.
    • The company boosted its forecast for full-year EPS to $1.71-$1.76, up from a prior range of $1.55-$1.60 and above the consensus estimate of analysts of $1.60.(PR)
    | Nov. 5, 2013, 12:49 PM
  • Nov. 5, 2013, 12:46 PM
    | Nov. 5, 2013, 12:46 PM
  • Aug. 9, 2013, 3:30 PM
    • The Justice Department has filed suit against PharMerica (PMC -6%) claiming it violated the False Claims Act and the Controlled Substances Act by dispensing controlled drugs without valid prescriptions and causing claims for illegally dispensed drugs to be submitted to the Medicare program.
    • The complaint alleges that PMC routinely dispensed Schedule II controlled drugs in non-emergency situations without first obtaining a written prescription from a treating physician, then knowingly submitted false claims to Medicare for the improperly dispensed Schedule II drugs.
    | Aug. 9, 2013, 3:30 PM
  • Jul. 9, 2013, 9:38 AM

    PharMerica (PMC -3.5%) takes a hit after Barclays downgrades the stock to Underweight from Equalweight and slashes the price target on the shares to $12 from $16. Analyst Brendan Strong doesn't like the loss of the Kindred contract and cuts his FY14 EPS estimate to $1.10 versus consensus of $1.51.

    | Jul. 9, 2013, 9:38 AM
  • Jun. 21, 2013, 12:45 PM
    Midday top 10 gainers: ORMP +36%. USMD +28%. NVGN +20%. UAMY +19%. CYTK +19%. SPRD +17%. IMMU +17%. OSIS +13%. INPH +13%. HWAY +13%.
    Midday top 10 Losers: IDIX -34%. BPAX -18%. PMC -17%. EBIX -17%. ELP -15%. CLNT -15%. NBG -9%. ORCL -9%. EDMC -9%. DSS -9%.
    | Jun. 21, 2013, 12:45 PM | 2 Comments
  • Jun. 21, 2013, 9:34 AM
    PharMerica (PMC -9.2%) slides after saying Kindred Healthcare (KND -1.6%) will not renew a skilled nursing pharmacy services contract when it expires in December. (8-K)
    | Jun. 21, 2013, 9:34 AM
  • Apr. 12, 2013, 4:16 PM

    PharMerica (PMC) names David W. Froesel, Jr. as interim Chief Financial Officer, effective immediately. Mr. Froesel, who was CFO of Omnicare from 1996 to 2009, and succeeds Michael J. Culotta, who by mutual agreement with the company, has stepped down to pursue other interests. Shares -1.7% AH.

    | Apr. 12, 2013, 4:16 PM
  • Feb. 11, 2013, 12:59 PM

    PharMerica (PMC -3.3%) dips as RBC Capital cuts the shares to Sector Perform on valuation following last weeks earnings report, saying that the nursing home pharmacy's reached it's $15 price target and coupled with declining sales, it doesn't see any incremental catalysts for growth over the near-term.

    | Feb. 11, 2013, 12:59 PM
  • May 3, 2012, 2:30 PM
    PharMerica (PMC +3.7%) moves up after beating Q1 estimates late yesterday. Total revenue actually declined 6.8% Y/Y, but margins were boosted by stronger cash flow. RBC ups the shares to Outperform on the report, citing valuation, better visibility and positive earnings growth.
    | May 3, 2012, 2:30 PM
  • Feb. 21, 2012, 9:58 AM

    Omnicare (OCR -0.5%) withdraws its hostile offer for nursing-home pharmacy company PharMerica (PMC -2.6%) a month after federal regulators raised antitrust issues. PMC says it is "pleased" with the decision, believing that the offer undervalued the company; OCR says it will provide an update to strategies on Thursday, when it reports its Q4 results.

    | Feb. 21, 2012, 9:58 AM
  • Feb. 9, 2012, 5:52 PM
    PharMerica (PMC): Q4 EPS of $0.27 beats by $0.06. Revenue of $495.6M (+0.8% Y/Y) misses by $10M. Shares +3.1% AH. (PR)
    | Feb. 9, 2012, 5:52 PM
  • Jan. 30, 2012, 10:01 AM
    Though PharMerica (PMC -12.6%) remains off sharply following the FTC's decision to block Omnicare's (OCR -1.4%) hostile bid, the company says it's pleased with the move. Meanwhile, Barclays and Cowen recommend buying Omnicare on any post-FTC weakness, arguing its fundamentals are sound regardless of whether a merger occurs.
    | Jan. 30, 2012, 10:01 AM
  • Jan. 30, 2012, 9:00 AM

    Premarket gainers: PBY +25%. GTXI +24%. TNB +23%. AMLN +14%. LCC +7%. ARNA +7%. PTNR +4%.
    Losers: CTIC -18%. PMC -14%. DB -6%. ING -5%. BCS -5%. MT -5%. CHU -4%. STD -4%. AKS -3%. DANG -3%. PLX -3%. PT -3%. JASO -3%. KOG -3%. X -3%. ANR -3%. RIG -3%.

    | Jan. 30, 2012, 9:00 AM
Company Description
PharMerica Corp. is an institutional pharmacy service company, which provides healthcare facilities in the U. S., pharmacy management services to hospitals, specialty infusion services to patients outside a hospital setting, and offers the only national oncology pharmacy and care management... More
Sector: Services
Industry: Drug Stores
Country: United States